This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Serrano-Fabiá, A. Articles by Jiménez-Torres, N. V. PubMed PubMed Citation Articles by Serrano-Fabiá, A. Articles by Jiménez-Torres, N. V. Social Bookmarking                         What's this?

Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy

¹ Hospital Manacor
² Hospital Universitario Dr. Peset and Universidad de Valencia
³ Hospital Universitario Dr. Peset
⁴ Hospital Manacor and Universidad de Valencia

^* To whom correspondence should be addressed. E-mail: serrano_ampfab{at}gva.es.

	Abstract

Objective. To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients.

Design. A longitudinal, prospective 2-year (January 2003 –to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology. MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance.

Variables. Number of MEs per 1000 patient-days, percentage according to the stage of the pharmacotherapeutic process and the severity of intercepted ME (scored from 1 = no damage to the patient, to 5 = patient death).

Results. A total of 1311 patients were receiving treatment, and MEs were identified in 225. Out of a total of 13,158 patient-days, 276 MEs were detected, equivalent to 20.9 MEs per 1000 patient-days; of these, 16.8 MEs per 1000 patient-days (80%) were intercepted and did not affect any patient.

The detected ME distribution according to pharmacotherapeutic stage was: prescription 75.7%, preparation 21.0%, dispensing 1.8%, administration 1.1%, and follow-up 0.4%. ME distribution according to severity was: grade 1 : 15.9%, grade 2 : 49.6%, grade 3 : 33.7%, grade 4 : 0.7%, and grade 5 : 0%.

The system intercepted 98.9% of all MEs with severity 3 (MEs with a potential for causing patient damage).

Conclusions. The multidisciplinary system with a well-established CPP detects 20.9 MEs per 1000 patient-days and intercepts 98.8% of all MEs with a potential for causing patient damage.

First published on July 17, 2009
Journal of Oncology Pharmacy Practice 2009, doi:10.1177/1078155209340482


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?